RenalytixAI Reaches Milestone of KidneyIntelX Commercial Testing with Mount Sinai Health System
September 18, 2020
Salt Lake City-based RenalytixAI, today announced the commercial launch of the KidneyIntelX clinical test reporting platform within the Mount Sinai Health System. This means that KidneyIntelX risk assessment of progressive decline in kidney function or kidney failure, including education support for treating clinicians, is now commercially available for patients with early stage diabetic kidney disease (DKD).
“This development underscores the leadership of RenalytixAI in addressing chronic kidney disease, from diagnosis to drug discovery,” said Kelvyn Cullimore, president and CEO of BioUtah.
RenalytixAI plans to continue to add to the quality and capability of the KidneyIntelX platform, designed to provide potentially critical new information about the rate of disease progression and risk of kidney failure in early stage kidney disease. Last month, the company announced a study with Mt. Sinai to monitor and predict kidney risk in COVID-19 patients.
Recent News
- Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
- BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease
- Lessons in Innovation: Clark Turner’s Impact on Medical Imaging
- Merit Medical Acquires Biolife Delaware
- Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
